Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)

Krystal Biotech (KRYS) Prices 2.67M Share Offering at $75/sh

Krystal Biotech, Inc. (NASDAQ: KRYS) the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Companys common stock offered in the public offering. The gross proceeds to the Company from this offering are expected to be approximately $200 million, before deducting the underwriting discounts and commissions and other... More

Merck (MRK) Announces KEYTRUDA Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Mercks anti-PD-1 therapy, has been approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) for the first-line treatment of patients with radically unresectable, advanced or recurrent esophageal carcinoma in combination with chemotherapy (5-fluorouracil [5-FU] plus cisplatin) based on data from the Phase 3 KEYNOTE-590 trial.

In Japan,... More

Krystal Biotech (KRYS) Announces Proposed $200M Stock Offering

Krystal Biotech, Inc. (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it has commenced a $200 million underwritten public offering of its common stock. The Company and certain selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional $30 million of the shares of the Companys common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the... More

Krystal Biotech (KRYS) PT Raised to $111 at Cowen

Cowen analyst Ritu Baral raised the price target on Krystal Biotech (NASDAQ: KRYS) to $111.00 (from $89.00) while maintaining an Outperform rating.

The analyst commented, "KRYS announced positive topline data from the Ph3 GEM-3 trial of Vyjuvek (fka B-VEC) in DEB. The study met its... More

Twitter (TWTR) CEO to Step Down - Reuters

Twitter (NYSE: TWTR) CEO Jack Dorsey expected to step down - Reuters